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The HIV-1 Vif protein counteracts the antiviral activity exhibited by the host cytidine deaminases APOBEC3G and
APOBEC3F. Here, we show that defective vif alleles can readily be found in HIV-1 isolates and infected patients. Single
residue changes in the Vif protein sequence are sufficient to cause the loss of Vif-induced APOBEC3 neutralization.
Interestingly, not all the detected defects lead to a complete inactivation of Vif function since some mutants retained
selective neutralizing activity against APOBEC3F but not APOBEC3G or vice versa. Concordantly, independently
hypermutated proviruses with distinguishable patterns of G-to-A substitution attributable to cytidine deamination
induced by APOBEC3G, APOBEC3F, or both enzymes were present in individuals carrying proviruses with completely or
partly defective Vif variants. Natural variation in Vif function may result in selective and partial neutralization of
cytidine deaminases and thereby promote viral sequence diversification within HIV-1 infected individuals.
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Introduction
A variety of intrinsic mechanisms that protect organisms
from retroviral infection and corresponding viral escape
strategies have evolved as a consequence of the coexistence
of retroviruses and vertebrates [1–4]. Lentiviruses, e.g.,
express Vif proteins that counter the antiretroviral activities
of DNA-editing enzymes APOBEC3G [5–8] and APOBEC3F
[9–12] by inducing their degradation by proteasomes
[7,8,13–15].
While both APOBEC3G and APOBEC3F (and, to a lesser
extent, APOBEC3B) exhibit anti-HIV-1 activity [9–12,16],
APOBEC3F appears less potent than APOBEC3G and is
partially resistant to HIV-1 Vif [11]. Importantly, the
expression of APOBEC3G and APOBEC3F seems to be
coordinated, probably because they have arisen by gene
duplication/ recombination and possess highly homologous
promoters. Both are expressed in cell populations susceptible
to HIV-1 infection [9,11,17].
APOBEC3G- or APOBEC3F-catalyzed deamination is not
highly sequence-speciﬁc, and many cytidines on the minus
strand of nascent retroviral genomes or reporter genes can be
deaminated [12,14,18–20]. However, dinucleotide context
strongly inﬂuences the efﬁciency with which cytidine deam-
ination occurs, such that 59-dCdC and 59-dTdC are the
favored dinucleotides targeted by APOBEC3G and APO-
BEC3F, respectively [9,11,20,21]. Cytidine deamination events
can be manifested as G-to-A changes on the plus strand of the
viral genome [11,12,14,19–21], and incomplete suppression of
cytidine deaminases by HIV-1 Vif might explain the
adenosine biased nucleotide composition of the HIV-1
genome. Similarly, the occasional occurrence of hypermu-
tated genomes containing numerous G-to-A changes [22–26]
could reﬂect occasional inactivating mutations in HIV-1 Vif.
Overall, it seems likely that Vif-mediated protection of HIV-1
genomes from host-mediated viral cDNA deamination in vivo
is not absolute.
Thus far, analyses of natural variation in HIV-1 Vif
function have been restricted to prediction of defects
resulting from gross mutations (e.g., missing translation
initiation or premature stop codons). Indeed, some reports
suggest that long-term non-progressors (LTNPs) harbor
grossly mutated Vif more frequently than do those with
progressive HIV disease [27]. However, this is not a
consistent ﬁnding [28,29]. Because natural variation in the
function of apparently intact HIV-1 vif alleles remains
largely unexplored, we examined the extent of variation in
APOBEC3G and APOBEC3F neutralizing activity among
naturally occurring HIV-1 Vif variants. Surprisingly, we
found that apparently intact but inactive Vif variants are
frequently detected in viral sequences from very different
sources. Importantly, we also found Vif variants that
selectively fail to neutralize APOBEC3G and/or APOBEC3F
activity, as well as proviruses in LTNPs that appeared to be
independently hypermutated as a result of APOBEC3G or
APOBEC3F action. These studies indicate that sporadic
inactivation of Vif likely occurs rather frequently in vivo,
and that natural variation in Vif function is likely to
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sequence evolution within HIV-1-infected individuals.
Results
Naturally Occurring Vif Diversity
Two distinct sources of Vif alleles were selected in order to
either maximize or minimize the occurrence of inactive
variants. The ﬁrst group was derived from uncultured DNA
isolated from peripheral blood mononuclear cells (PBMCs) of
three extensively studied individuals (P1, P2, and P3) with
non-progressive HIV-1 infection for more than 20 y [28, 30–
35]. We reasoned that the very low (undetectable) level of
HIV-1 replication that occurs in these individuals would
maximize the chances of detecting naturally occurring
defective vif alleles, because replication-defective HIV-1
variants should not be obscured by superimposed replicating
virus. Moreover, some viral DNA sequences in these
individuals contained numerous G-to-A changes in the 59LTR
(P2) [33] and in gag (P3) [31]. Ampliﬁcation and sequence
analysis of APOBEC3G mRNA from all three LTNPs excluded
the possibility that hypermutation of viral sequences was due
to the existence of a naturally occurring Vif-resistant
APOBEC3G mutant (data not shown).
A second set of Vif variants was derived from four short-
term HIV-1 isolates (V1, V2, V3, and V4) [36]. Vif variants
were cloned after a limited period of co-culture of patient
cells with ‘‘non-permissive’’ PBMCs, so as to provide a
selective pressure for active vif alleles while minimizing the
introduction of new mutations. V1, V3, and V4 were obtained
from recently infected individuals, and V2 was obtained from
a chronically infected patient. Table S1 provides a summary
of characteristics of the patients from which viral isolates and
DNA were obtained.
The phylogenetic relationships among a total of 79
independent vif sequences obtained from these sources is
depicted in Figure 1. For each of the LTNPs, a set of Vif
sequences collected in 1993–1994 [28] as well as from one or
two additional time-points were included (see Material and
Methods). Because the neighbor-joining analysis revealed no
discernable temporal inﬂuence on phylogeny in P1, P2, and
P3, the observed intra-individual sequence variation likely
represents a spectrum of archived proviruses rather than
ongoing sequence evolution. Consensus vif sequences from
each individual or isolate diverged by 3–9% from a prototype
vif allele (from HIV-1 NL4–3), a value typical of North
American subtype-B vif sequences (Figure 1).
While the majority of vif sequences derived from LTNPs
and viral isolates encoded a full-length protein (192 residues),
six sequences (from P2, P3, and V4) contained one or more
premature stop codons. Interestingly, each of these resulted
from a G-to-A mutation in the context of a Trp codon (TGG
to TAG). In addition, a subpopulation of obviously defective
Vif sequences from P3 (Figure 1) contained numerous G-to-A
substitutions. Thus, expression of intact Vif proteins can be
abolished by relatively rare G-to-A substitutions at trypto-
phan sites, or by overt hypermutation.
Frequent Occurrence of Non-Functional Vif
Simple inspection of sequences for obviously inactivating
mutations likely underestimates the frequency of inactive vif
alleles, and would not identify weakly active Vif proteins.
Therefore, we employed a functional test to measure Vif
Figure 1. Naturally Occurring vif Sequence Variation
The phylogenetic relationships among 79 independent vif sequences
derived from patients (P1, P2, P3) and viral isolates (V1, V2, V3, V4) were
analyzed using the Neighbor-joining method. Seven subtype B reference
sequences and a consensus subtype B sequence were also included. A
cluster of hypermutated vif sequences found in P3 is indicated. The 40
distinct protein variants selected for functional testing are identified by  .
For each patient and isolate, an individual vif consensus sequence was
generated and the percent divergence of each vif consensus sequence
from the NL4–3 vif referenced is shown.
DOI: 10.1371/journal.ppat.0010006.g001
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Synopsis
Host cells express DNA-editing enzymes, termed APOBEC3G and
APOBEC3F, that are capable of profoundly attenuating the
replication of retroviruses. However, human immunodeficiency
viruses use an efficient approach to ‘‘neutralize’’ these cellular
enzymes: specifically, the viral gene vif counters the antiretroviral
activity of APOBEC3G and APOBEC3F by inducing their degradation.
This study systematically analyzes natural variation in the ability of
Vif to neutralize APOBEC-mediated HIV-1 editing and demonstrates
that some Vif mutants selectively fail to efficiently ‘‘silence’’
APOBEC3 enzymes. These findings extend the conventional view
that errors of reverse transcription and recombination are largely
responsible for the rapid evolution of HIV-1 in vivo. Indeed, variation
in Vif function may profoundly impact the extent and direction of
viral sequence evolution within HIV-1-infected individuals. Thus,
innate cellular defenses that likely evolved to restrict retroviral
replication might have been usurped by HIV to accelerate viral
sequence diversification and escape from immune control and
inhibition by antiretroviral drugs.activity. We generated VSV-G pseudotyped HIV-1 vector
particles in the presence of APOBEC3G or APOBEC3F and
patient/isolate-derived Vif proteins and measured their
infectivity using a reporter cell-line (Figure 2). Under these
conditions, HIV-1 infectivity was reduced more than 100-fold
by APOBEC3G and restored by HIV-1 (NL4–3) Vif to 35–45%
of the level observed in the absence of APOBEC3G (Figure
2A). APOBEC3F was a less potent inhibitor of HIV-1 and
reduced infectivity by 15- to 20-fold, as has been recently
reported [11]. Additionally, APOBEC3F was more resistant to
neutralization by NL4–3 Vif, which restored infectivity to
about 15% to 25% of its uninhibited level, even at the
maximum level of Vif expression tested. The linear range of
the assay with respect to the amount of transfected Vif
expression plasmid was determined (Figure 2A), and levels of
Vif expression within this range were used in subsequent
experiments.
We next selected a panel of 40 representative and
apparently intact Vif proteins from the 79 independent
clones and measured their ability to neutralize APOBEC3G
antiviral activity. The majority of patient- and isolate-derived
Vif proteins exhibited similar activity to that of NL4–3 Vif
(Figure 2B). However, each set of patient-derived and isolate-
derived Vif proteins contained at least one variant that was
either inactive or only weakly active (Figure 2B). In fact, nine
of the 40 apparently intact Vif proteins were non-functional
despite the fact that they were well expressed. One additional
amino-terminally truncated Vif variant (V4–8) that contained
a stop at codon 11 but was expressed via an alternative
translation initiation site at codon 16 was found to be
inactive. Five additional vif variants (P2, P3) that contained
premature stop codons were assumed to be inactive. There-
fore, of the 79 sampled vif alleles, comprising 61 distinct
proteins, at least 15 were unable or poorly able to counteract
APOBEC3G antiviral activity (Figure 2C). Additionally, even
among functional Vif variants, there was signiﬁcant variation
in the extent to which they restored HIV-1 infectivity that was
not explained by variation in expression level (Figure 2B, and
data not shown).
Mutations Conferring Loss of APOBEC3G- and/or
APOBEC3F-Neutralizing Activity
To determine the amino acid substitutions responsible for
functional inactivation of apparently intact Vif proteins, we
identiﬁed the closest functional relative of each non-func-
tional variant. In most cases, we could identify functional and
non-functional Vif proteins that differed by only one or two
amino acids (Figure S1). Of note, two mutations (G138R and
L150P) that were found only in non-functional variants arose
independently in unrelated Vif proteins (from P1, P2, and/or
Figure 2. Activity of Vif Variants from Patients and Viral Isolates
(A) Infectivity of HIV-1 vector particles generated by transient transfection of 293T cells in the presence or absence of fixed amounts of APOBEC3G or
APOBEC3F and the indicated amounts of HIV-1 NL4–3 Vif expression plasmids was determined, as described in the Materials and Methods.
Representative results from one out of three independent experiments are depicted. Infectivity measurements were performed in duplicate assays, and
the error bars represent the standard deviation of the RLU values. RLU, relative light units.
(B) APOBEC3G neutralization by Vif proteins from LTNPs (P1, P2, P3) and viral isolates (V1, V2, V3, V4). The infectivity of particles generated in the
presence of APOBEC3G and each Vif protein is expressed relative to the infectivity of particles generated in the absence of APOBEC3G and Vif. Each Vif
protein is identified by its source (e.g., P1, V1) and a variant number (e.g., P1–2). The data represents the average infectivity values of at least three
independent experiments, with the error bars showing the standard deviations.
(C) Summary of the properties of Vif variants. Independent sequences were defined as alleles that were derived from different PCR reactions or had
different nucleotide sequences. Because some changes are synonymous, not all independent sequences encode variant proteins. Vif variants with gross
defects (e.g., premature stop codons) as well as those that were found to be inactive in the functional assay are designated ‘‘defective Vif.’’ The overall
frequency of inactive Vif proteins is expressed as a percentage relative to the number of independent sequences.
DOI: 10.1371/journal.ppat.0010006.g002
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no very closely related functional counterpart was identiﬁed
was from patient DNA (P2–7) which differed at four positions
from its closest functional relative (W11R, K63E, G75R,
G185R) and was not analyzed further.
We tested the panel of ‘‘matched’’ functional and non-
functional Vif variants for their relative ability to neutralize
APOBEC3G and APOBEC3F. Like NL4–3 Vif, those that
neutralized APOBEC3G also neutralized APOBEC3F, albeit
less efﬁciently (Figure 3B and 3C). Generally, the matched
variants that were inactive or weakly active against APO-
BEC3G also failed to neutralize APOBEC3F. However, two Vif
variants (V2–5, P3–5) that contained mutations K22E and
Y40H, respectively, were unusual in that they did not
neutralize APOBEC3G but retained partial activity against
APOBEC3F (Figure 3B and 3C).
To conﬁrm these ﬁndings and to unambiguously identify
the mutations responsible for loss of function, we constructed
a panel of NL4–3 Vif mutants containing naturally occurring
mutations that were associated with loss of APOBEC3G
neutralization. The W11R mutant was added to this panel, as
this was the only substitution in the non-functional P2–7
variant (which contained three additional substitutions, see
above) that occurred at a position that is invariant in the
HIV-1 sequence database.
In the presence of APOBEC3G, NL4–3 Vif harboring the
mutations K22E, S32P, Y40H, E45G, F115S, G138R, or L150P
failed to restore HIV-1 infectivity (Figure 4A). Conversely,
NL4–3 Vif containing the mutations W11R or G143R
displayed activity close to that of unmutated NL4–3 Vif.
Most of the mutants exhibited similar loss or retention of
activity against APOBEC3F as against APOBEC3G (compare
Figures 4A and 4B). Western blotting of transfect cell lysates
revealed that expression levels of the Vif mutants that fail to
rescue particle infectivity were comparable or superior to the
expression level observed for NL4–3 Vif (Figure 4C).
Interestingly, mutants W11R, K22E, Y40H, and E45G dis-
played a selective propensity to neutralize one of the two
APOBEC3 proteins. These mutants were analyzed in more
detail by measuring viral infectivity in the presence of
APOBEC3G or APOBEC3F and varying levels of Vif (Figure
4D). This analysis revealed that the K22E mutant retained
partial activity against APOBEC3F but was inactive against
APOBEC3G. The Y40H and E45G Vif mutants neutralized
APOBEC3F activity almost as efﬁciently as wild-type NL4–3
Vif, but displayed only weak activity against APOBEC3G.
Conversely, the W11R mutant exhibited the precisely
opposite phenotype and neutralized APOBEc3G but not
APOBEC3F. Thus, naturally occurring mutations can result in
Vif variants that neutralize one but not the other cytidine
deaminase.
In Vivo Sequence Diversity Consistent with Selective
Exposure to APOBEC3G or APOBEC3F
In principle, mutations that selectively affect the ability of
Vif to neutralize APOBEC3G and/or APOBEC3F could
profoundly affect HIV-1 sequence evolution. Because we
found defective Vif variants in patients who also contained G-
to-A hypermutated viral DNA (P2 and P3) [31,33], we next
obtained a more extensive sample of Gag-Pol sequences from
patients and viral isolates harboring defective Vif alleles (a
total of 25 independent Gag-Pol sequences of which 13
representative sequences are depicted in Figure 5).
In general, the Gag-Pol sequences from the LTNPs
contained about 3-fold fewer changes relative to an NL4–3
HIV-1 reference sequence than did the viral isolate sequen-
ces. This is perhaps due to the fact that the three LTNPs
became infected more than 20 y ago, quite early in the North-
American HIV-1 epidemic and around the time the viral
isolate NY5, which comprises the 59 portion of the reference
sequence NL4–3 [37], was obtained. Conversely, the viral
isolates were derived from patients infected in the late 1990s.
Nonetheless, the fraction of changes relative to the reference
sequence that were G-to-A mutations was quite similar for
patient and viral isolate sequences (about 25% of all changes)
and higher than would be expected if nucleotide substitutions
were random (Figure 5B). This phenotype was exaggerated in
several P2- and P3-derived sequences that were clearly
hypermutated. In some cases, examples of which are shown
in Figure 5A and 5B, about 65–70% of all changes relative to
the reference sequence were G-to-A changes. In P1, no
obviously hypermutated viral sequences were detected, while
in P2 and P3, viral DNA was often hypermutated and
defective. Indeed, hypermutated Vif sequences were previ-
ously detected in P3 (see Figure 1).
In principle, G-to-A mutations can occur in one of four
different dinucleotide contexts. We sequenced hrGFP-con-
taining viral DNA generated following infection with HIV-1
vectors assembled in the presence of APOBEC3G or
APOBEC3F. Consistent with recent reports [9,11], APO-
BEC3F primarily induced GA-to-AA changes and very few
GG-to-AG changes in hrGFP. Conversely, APOBEC3G caused
twice as many GG-to-AG as GA-to-AA changes (Figure 5B). In
the sequences from all the isolate-derived DNA as well as in
some patient-derived Gag-Pol clones (e.g., P1–29, P3–11; Fig-
ure 5B), GA-to-AA changes were more prevalent than GG-to-
AG changes, relative to the reference sequence, suggesting
that HIV-1 is more often mutated by APOBEC3F than by
APOBEC3G. In contrast, in the extensively hypermutated
Gag-Pol clones (e.g., P2–21, P2–31, P3–2, Figure 5A and 5B)
there was an approximately 2:1 ratio of GG-to-AG versus AG-
to-AA substitutions, which closely recapitulated the result of
APOBEC3G- (and not APOBEC3F-) induced hrGFP muta-
genesis.
Because the p17MA region of Gag provided a reasonable
representation of mutations present in Gag-Pol, and because
p17MA sequences present in P3 had previously been
extensively sampled [31], we restricted a more detailed
phylogenetic analysis to this region. Thus, the larger dataset
comprised a total of 70 p17MA sequences, and the phyloge-
netic analysis is depicted in Figure 6A. Notably, the p17MA
sequences obtained from a single individual harboring
numerous hypermutated proviruses (P3) were exceptionally
heterogeneous and exhibited greater diversity than that
observed among a selection of subtype B reference sequences.
While very diverse hypermutated sequences co-existed in a
patient and sometimes within a single sample (Figure 6B),
sampling bias due to the very low number of proviruses
present in these LTNPs makes it difﬁcult to derive con-
clusions about temporal variation in the proportion of
hypermutated to ‘‘normal’’ sequences. Nonetheless, it was
clear that in some individuals at some time-points, hyper-
mutated sequences predominated. Notably, individual
PLoS Pathogens | www.plospathogens.org September 2005 | Volume 1 | Issue 1 | e6 0023
Vif, APOBEC3G/3F Neutralization, HIV-1 Evolutionp17MA clones contained distinct patterns of G-to-A sub-
stitutions that reﬂect the generation of multiple, independ-
ently hypermutated proviruses within a single individual.
Moreover, some clones almost exclusively harbored GG-to-
AG changes relative to the reference sequence (e.g., P2–3, P2–
5, P3–8, P3–9, Figure 6B), while in others GA-to-AA changes
predominated (e.g., P3–13, P3–14, Figure 6B). In other clones,
GG-to-AG and GA-to-AA substitutions occurred in variable
proportions. This bias recapitulated the footprints expected
to result from mutation induced either by APOBEC3G,
APOBEC3F, or a mixture of both and is likely, therefore, the
result of variation in the ability of Vif, within an individual, to
neutralize these cytidine deaminases.
Discussion
Host cells use DNA-editing enzymes such as APOBEC3G
and APOBEC3F to inhibit the replication of exogenous and
endogenous retroviruses [38,39]. In turn, lentivirus Vif
proteins counter the antiretroviral activity of these cytidine
deaminases [5–12] by inducing their degradation.
While defective vif alleles should render the majority of
HIV-1 progeny virions noninfectious, establishment of
proviruses that have APOBEC3G- and/or APOBEC3F-in-
duced mutations should endow the proviral population with
additional diversity beyond that resulting from error-prone
reverse transcription [1,3]. Here, we show that defective vif
alleles are easily found, even in a relatively small sample of
viral isolates and uncultured viral DNA from infected
individuals. Because active and defective Vif variants were
detected in similar proportions (about 19%) in LTNP DNA
and viral isolates, it seems probable that Vif is sporadically
inactivated at some frequency by reverse transcriptase errors
or cytidine deamination in all HIV-1-infected individuals. We
also found multiple, independent hypermutated proviruses in
two of the three LTNPs studied. It is likely that the relative
ease of detection of extensively hypermutated proviruses is
an unusual property of LTNPs [26] and hypermutated
proviruses are only rarely detected in other situations
because they are obscured by superimposed replication
competent virus. Put another way, the ease of detection of
hypermutated HIV-1 is likely a consequence, rather than a
cause, of LTNP status.
A recent report provides independent evidence for the
occurrence of sporadic Vif inactivation in vivo: indeed, more
than 9% of proviral sequences derived from resting CD4þ
cells of HAART-treated patients with plasma viremia below
the level of detection were found to be hypermutated [40].
Site-directed mutagenesis studies revealed a number of
residues and domains located throughout Vif that are
essential for infectivity and viral replication in non-permis-
sive cells [41–44]. We identiﬁed here several examples of
Figure 3. Closely Related Vif Proteins Display Distinct Functional
Properties
(A) Summary of the residues implicated as causing Vif defects by
comparison of functional and non-functional Vif variants. Amino acid
substitutions that occurred exclusively in non-functional Vif proteins are
depicted relative to the NL4–3 Vif sequence. Changes identified by * are
caused by G-to-A mutations.
(B, C) Function of closely related vif alleles assessed by quantitation of
the infectivity of particles produced in the presence of APOBEC3G (B) or
APOBEC3F (C). Amino acid substitutions in the non-functional partner of
the ‘‘matched’’ functional Vif variant are given in parentheses in (B). The
dotted line in (C) indicates the level of infectivity observed for the vector
generated in the presence of APOBEC3F and in the absence of Vif. The
data represent the average infectivity values of at least three
independent experiments, with the error bars showing the standard
deviations.
DOI: 10.1371/journal.ppat.0010006.g003
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defects in APOBEC3G- or APOBEC3F-neutralizing activity.
Interestingly, these occurred toward the amino-terminus of
Vif, while those causing general defects occurred either near
the amino-terminus or close to the functionally important
SLQ motif [41,42,45]. These ﬁndings suggest the possibility
that the Vif amino-terminal domain contains determinants
that confer speciﬁc binding to APOBEC3G or APOBEC3F.
Such mutations should cause nascent viral DNA to be
exposed either to APOBEC3G or APOBEC3F or both, with
the induction of very different patterns of G-to-A changes
in the viral quasi-species. Due to the nature of sampling
proviral DNA in a patient, it is practically impossible to link
a particular Vif point mutant to a subsequently generated
hypermutated provirus. Nonetheless, even within a tiny
fraction of the total burden of, e.g., P39s HIV-1 sequences,
Vif variants that selectively failed to neutralize APOBEC3G
as well as p17MA sequences bearing the footprint of
selective mutation by either cytidine deaminase were rather
easily detected (Figure 6). Selective and sporadic loss of
cytidine deaminase neutralization can result in massive
sequence variation. Indeed, the extent of p17MA sequence
diversity within one of the individuals studied herein (P3)
surpassed the variation observed among a selection of
subtype B reference sequences and contemporary isolates.
While the bulk of hypermutated proviruses are replication
defective, they could, in principle, provide a genetic
‘‘resource,’’ and selected fragments could easily be recom-
bined into the circulating viral population as cells harboring
them become super-infected. Moreover, while intermittent
inactivation of Vif has the measurable consequence of
deposition of hypermutated proviruses, this likely represents
an extreme manifestation of the loss-of-function phenotype.
It is quite likely that more subtle (and less easily measurable)
variation in Vif’s anti-APOBEC3G and anti-APOBEC3F
activities occurs at greater frequency than the roughly
20% inactivation documented herein. It is also interesting
that some of the mutations that affected Vif function were
themselves the result of G-to-A changes. Thus, ‘‘feedback’’
loops of Vif mutation resulting in more or less mutation of
Vif and other viral genes could result from variation in Vif
function.
The high adenosine content of lentiviral genomes [22] and
the sporadic detection of hypermutated genomes in vivo [23–
26] suggest that cytidine deamination provides an important
source of viral diversiﬁcation. Thus, an activity that likely
evolved as a host defense against viruses might have been
usurped and may facilitate HIV-1 escape from immunological
and pharmacological inhibition. In addition, an appreciation
of the respective contributions of viral and host-mediated
Figure 4. Effect of Naturally Occurring Single Amino Acid Substitutions on NL4–3 Vif APOBEC3G and APOBEC3F Neutralization Activity
The HIV-1 vector infectivity generated in the presence of APOBEC3G (A) and APOBEC3F (B) and a fixed dose of NL4–3 Vif mutant was measured. The
dotted line in (B) indicates the level of infectivity observed for the vector generated in the presence of APOBEC3F and in the absence of Vif. The data
represent the average infectivity as determined by at least three independent experiments, with the error bars showing the standard deviations. (C)
Protein expression levels of the NL4–3 Vif mutants were determined by Western blotting of transfected 293T cell lysates. (D) Infectivity of HIV-1 vector
generated in the presence of APOBEC3G (filled symbols) and APOBEC3F (open symbols) and varying levels of selected Vif mutants.
DOI: 10.1371/journal.ppat.0010006.g004
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mining the potential efﬁcacy and the potential risks
associated with the use of antiretroviral strategies that target
vif:APOBEC3G/3F interactions.
Materials and Methods
Patient-derived and NL4–3 mutant vif alleles. DNA was extracted
from either patient’s PBMCs (P1, P2, and P3), or from PBMCs used for
viral propagation (V1, V2, V3, V4) using DNeasy DNA isolation kit
(Qiagen, Valencia, California, United States). Samples were obtained
in 1995 and 2000 for P1, in 2000 and 2001 for P2, and 2003 for P3.
Because clinical materials from the mid-1990s were not available for
P3, we reconstructed the two P39s vif alleles that were previously
described and contained amino acid substitutions relative to a P3
sequence from 2003 (Y40H and F115S [28]). Full-length vif genes were
ampliﬁed by nested PCR using high-ﬁdelity polymerase and cloned
into the expression vector pCRV1, as previously described [46]. In
order to minimize sampling bias due to the very low proviral load in
some LTNP samples (e.g., less than ﬁve copies/10
6 PBMCs [30]),
multiple parallel PCR reactions were done. Cloned Vif variants were
sequenced in both directions and aligned using the DNAStar
(Madison, Wisconsin, United States) Version 4.03 software package.
Phylogenetic relationships were assessed by the Neighbor Joining
method (PAUP software). Site-directed mutations were introduced
into NL4–3 Vif using mutagenic oligonucleotides and recombinant
PCR resulting in NL4–3 Vif mutants encoding W11R, K22E, S32P,
Y40H, E45G, F115S, G138R, G143R, and L150P as well as the
previously described mutants C114S and C133S [47]. Wild-type and
mutant NL4–3 Vif proteins as well as the patient- and primary-
isolate-derived Vif variants were expressed using pCRV1.
Gag-Pol and p17MA sequence analysis. A region spanning the Gag,
protease (PR), and half of the reverse transcriptase gene (RT; total
3,094 nucleotides) was ampliﬁed from all three LTNPs and the four
viral isolates using nested PCR and the same DNA samples used as a
source of vif variants. PCR fragments were cloned into TOPO XL
vector (Invitrogen, Carlsbad, California, United States) and se-
quenced bidirectionally. To ensure appropriate sampling in the
setting of low proviral load, we performed multiple PCR reactions in
parallel and cloned the fragments from ﬁve to seven PCR reactions
separately. Phylogenetic relationships were assessed by the Neighbor
Joining method (PAUP software). Analysis of the G-to-A substitutions
was performed using the HYPERMUT program [48].
Assay for Vif function. HIV-1 vector particles were generated by
transfecting 293T cells with plasmids expressing HIV-1 gag-pol
(pCRV1/Gag-pol)[49], a packagable HIV-1 RNA genome that encodes
only Tat, Rev, Vpu, and GFP (pV1/hrGFP) and the G protein from
vesicular stomatitis virus (pHCMV VSV-G) in a 5:5:1 ratio. To
measure Vif function, cells were co-transfected with this plasmid
mixture and additional plasmids expressing amino-terminally HA-
tagged APOBEC3G or APOBEC3F and a pCRV1/Vif variant. Cells
were transfected in 24 well plates using LipoFectamine Plus reagent
(Invitrogen) and the supernatant harvested 48 h later and ﬁltered.
Infectivity was measured in duplicate assays using TZM-bl cells, which
carry an HIV-1 Tat responsive b-galactosidase indicator gene under
the transcriptional control of the HIV-1 promoter. Infection was
done in the presence of 8lg/ml Polybrene, and b-galactosidase
activity was quantiﬁed 48 h later using chemiluminescent substrate as
previously described [50].
Measurement of APOBEC3G- and APOBEC3F-driven hrGFP
mutagenesis. HIV-1 vector particles were generated by transfection
of 293T cells, as for the analysis of Vif function with two differences:
First, APOBEC3G or APOBEC3F but no Vif expression plasmid was
included in the transfection mixture. Second, to minimize the
possibility that transfected DNA rather than de novo synthesized
viral DNA would be ampliﬁed and sequenced, the pV1/hrGFP plasmid
vector was omitted from the transfection mixture and a 293T-derived
cell line carrying an integrated V1/hrGFP vector genome was used to
generate vector particles. Vector particles generated by this method
were used to infect MT4 cells and DNA was extracted 8 to 10 h later
using a DNeasy DNA isolation kit. hrGFP sequences were ampliﬁed by
PCR, cloned into TOPO vector, and sequenced bidirectionally.
Sequences (450-nucleotide fragment) from 10 to 15 clones were
aligned using the DNAStar software package.
Figure 5. Analysis of Gag-pol Sequences Derived from LTNP and Viral Isolates
(A) Graphic representation of the G-to-A changes (compared to HIV-1 NL4–3) present in Gag-pol. Analysis was performed using the HYPERMUT program
[48].
(B) Quantitative summary of the observed changes. ‘‘# diff’’ is the number of positions at which the patient sequence differs from NL4–3. ‘‘# G-A (%)’’
represents the absolute number and percentage of all substitutions that are G-to-A changes. The dinucleotide context (GG, GA, GC, GT) reflects the two
contiguous bases, with G-to-A mutations occurring in the first position. The numbers of differences (‘‘# diff’’) for the APOBEC3G- and APOBEC3F-
induced changes in the in vitro assay are given as an average (6 standard deviation) of those occurring in 10 to 15 clones of hrGFP (450 nucleotides).
DOI: 10.1371/journal.ppat.0010006.g005
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Found at DOI: 10.1371/journal.ppat.0010006.sg001 (24 KB PDF).
Table S1. Summary of Clinical and Virological Characteristics of the
Four Patients from Whom Virus Was Cultivated As Well As from the
Three LTNPs Studied
Found at DOI: 10.1371/journal.ppat.0010006.st001 (16 KB PDF).
Accession Numbers
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bers for the vif and gag-pol sequences are DQ097739–DQ097768.
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